CTLA4 and melanoma: In melanoma patients, TIGIT+ Tregs exhibited greater immunosuppressive capabilities and stability than TIGIT- Tregs by increasing the expression of CTLA-4, CD39, PD-1, and TIM3 (Fourcade et al., 2018).